| Market Capitalization (Millions $) |
219 |
| Shares
Outstanding (Millions) |
72 |
| Employees |
49 |
| Revenues (TTM) (Millions $) |
54 |
| Net Income (TTM) (Millions $) |
12 |
| Cash Flow (TTM) (Millions $) |
-37 |
| Capital Exp. (TTM) (Millions $) |
0 |
Business Description
Siga Technologies Inc. is a biotechnology company that specializes in the development and commercialization of pharmaceutical products for use in the defense, medical and research sectors. The company was founded in 1995 by Dr. Eric Rose, and is headquartered in New York, New York. Siga Technologies is publicly traded on the NASDAQ exchange under the ticker symbol SIGA.
The primary focus of Siga Technologies' research and development efforts is on the development of drugs that can be used to treat diseases caused by bioterrorism agents such as smallpox, Ebola, and anthrax. The company has developed a number of proprietary antiviral and antibiotic therapeutics that have undergone clinical trials and have been approved by the U.S. Food and Drug Administration (FDA). One such antiviral drug is TPOXX, which is used to treat smallpox infections and has been stockpiled by the U.S. Department of Health and Human Services.
Siga Technologies operates in two primary segments: government and commercial. The government segment focuses on developing and testing drugs for use in biodefense and public health preparedness, and includes contracts with agencies such as the Department of Defense, the National Institutes of Health, and the Biomedical Advanced Research and Development Authority. The commercial segment focuses on exploring the use of Siga's drugs in other areas, such as the treatment of chronic viral diseases like hepatitis B and C.
The company has a strong commitment to research and development, and has formed partnerships with other biotechnology companies, academic institutions, and government agencies to advance its drug development programs. Siga Technologies employs a team of experienced researchers, scientists, and clinical experts who are committed to advancing the company's mission of developing effective treatments for infectious diseases.
Overall, Siga Technologies is a leading biotechnology company that specializes in developing highly effective drugs for use in the defense, medical, and research sectors. With its strong commitment to research and development and its focus on innovative drug development programs, the company is well-positioned to continue its growth and success in the years ahead.
Company Address: 31 East 62nd Street New York 10065 NY
Company Phone Number: 672-9100 Stock Exchange / Ticker: NASDAQ SIGA
|
100.99 %